U.S. Neuroscience Antibodies & Assays Market Hits US$ 1.7 Billion in 2024 | Set to Grow at 8.9% CAGR Through 2030

The U.S. Neuroscience Antibodies and Assays Market was valued at US$ 1.7 billion in 2024, supported by strong demand for advanced diagnostic tools, biomarker discovery, and neurodegenerative disease research. The market continues to expand as laboratories, biotech companies, and academic institutes increase investments in technologies that enable more precise detection and analysis of neurological pathways.

The segment forms a significant share of the global market, which is projected to grow at a CAGR of 8.9% through 2030, driven by rising cases of Alzheimer's, Parkinson's, and other CNS disorders. Growing adoption of high-throughput assays, monoclonal antibodies, and next-generation imaging reagents further strengthens the U.S. market's leadership position in neuroscience research and clinical development.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://www.datamintelligence.com/download-sample/neuroscience-antibodies-and-assays-market?sai-v

Neuroscience Antibodies and Assays Market refers to the industry that develops and supplies specialized antibodies and analytical assays used to study neurological disorders, brain function, and neural biomarkers in research and diagnostics.

Key Developments

United States
✅ June 2025: A leading U.S. biotech firm introduced an advanced CLEIA-based sTREM2 assay enabling rapid quantification of neuroinflammation biomarkers, strengthening research capabilities in Alzheimer's and other CNS disorders.

✅ May 2025: U.S. research groups partnered with AI-driven antibody discovery startups to accelerate identification of high-specificity antibodies for synaptic proteins and neurodegeneration-related targets.

✅ February 2025: North American laboratories increased adoption of next-generation consumables such as ELISA kits, antibody pairs, and multiplex assays due rising neurological disease prevalence and expanding clinical trial pipelines.

Japan
✅ July 2025: Japanese neuroscience institutes strengthened collaboration with domestic reagent manufacturers to co-develop specialized antibodies and assay kits for neurodegenerative biomarker detection.

✅ May 2025: Japan-based laboratories expanded use of multiplex immunoassay platforms for high-throughput neurological biomarker screening, improving accuracy in Alzheimer's and Parkinson's diagnostic research.

✅ March 2025: Universities and biotech firms accelerated development of new monoclonal antibodies optimized for synaptic protein analysis, supporting advanced neuronal signaling studies.

Mergers & Acquisitions

United States
✅ May 2025: A U.S. antibody technology developer entered a strategic partnership with a neuroscience-focused diagnostics company to expand assay development pipelines for CNS biomarkers.

Key Players:
Thermo Fisher Scientific | Bio-Rad Laboratories, Inc. | Merck KGaA | F. Hoffmann-La Roche | Cell Signaling Technology, Inc. | BioLegend, Inc. | Abcam Plc | Rockland Immunochemicals, Inc. | GenScript | Santa Cruz Biotechnology, Inc.

Key Highlights :

• Thermo Fisher Scientific - Holds 14.2% market share, driven by its extensive antibody portfolio, immunoassay kits, and high-throughput research tools.

• Bio-Rad Laboratories, Inc. - Accounts for 12.5% share supported by strong demand for its Western blotting reagents, flow cytometry antibodies, and multiplex immunoassays.

• Merck KGaA - Maintains 11.3% share through its broad range of primary and secondary antibodies used across proteomics, immunofluorescence, and clinical research.

• F. Hoffmann-La Roche - Holds 10.4% market share, driven by advanced diagnostic antibodies and integration with molecular biology platforms.

• Cell Signaling Technology, Inc. - Commands 9.6% share with strong leadership in signaling pathway antibodies and high-specificity research antibodies.

• BioLegend, Inc. - Accounts for 8.7% share fueled by rapid expansion in flow cytometry, recombinant antibodies, and immunology research reagents.

• Abcam Plc - Holds 7.5% share due to its extensive catalog of recombinant antibodies, proteins, and assay kits used globally in academic and biopharma R&D.

• Rockland Immunochemicals, Inc. - Maintains 6.2% share supported by antibody production, custom services, and specialized reagents for proteomics.

• GenScript - Holds 5.4% share driven by recombinant antibody technologies, gene-editing research tools, and custom antibody development services.

• Santa Cruz Biotechnology, Inc. - Contributes 4.7% share through a wide range of antibodies used for Western blotting, immunoprecipitation, and oncology research.

Purchase this report before year-end and unlock an exclusive 30% discount: https://www.datamintelligence.com/buy-now-page?report=neuroscience-antibodies-and-assays-market?sai-v
(Purchase 2 or more Repots and get 50% Discount)

Market Drivers

• Increasing prevalence of neurological disorders such as Alzheimer's, Parkinson's, epilepsy, and multiple sclerosis is driving demand for advanced antibodies and assays for diagnosis and research.

• Rapid growth in neurobiology research, supported by expanding funding for academic and commercial R&D across biomarkers, synaptic activity, and neuroinflammation.

• Rising adoption of high-sensitivity immunoassays and monoclonal antibodies in drug discovery, enabling better screening, target validation, and mechanistic studies.

• Technological advancements in imaging, flow cytometry, and multiplex assay platforms are enhancing accuracy and enabling large-scale neurobiological data analysis.

• Expanding pharmaceutical and biotech pipelines for neurodegenerative therapeutics is increasing utilization of specialized antibodies and assay kits.

Industry Developments

• October 2025 (US): Research institutions introduced next-generation monoclonal antibodies targeting amyloid and tau proteins to support early-stage Alzheimer's diagnostics.

• August 2025 (Germany): Biotech firms launched multiplexed neuroinflammation assay panels enabling simultaneous quantification of cytokines, chemokines, and glial markers.

• June 2025 (Japan): Neuroscience laboratories adopted high-throughput neuronal cell-based assay systems to accelerate CNS drug candidate screening.

• March 2025 (UK): Pharmaceutical companies partnered with reagent manufacturers to develop custom antibody libraries for neurodegenerative disease research.

Regional Insights
• North America - US$ 1.8 billion (40% share): Growth is driven by "strong biomedical research funding, large presence of neuroscience-focused universities, and rapid adoption of high-sensitivity immunoassay platforms in drug discovery."

• Europe - US$ 1.3 billion (30% share): Expansion is supported by "robust government initiatives for neurological research, increasing focus on biomarker development, and rising collaborations between academic and biotech institutions."

• Asia-Pacific - US$ 1.1 billion (25% share): Growth is fueled by "expanding neuroscience research centers, rising investment in neurodegenerative disease studies, and growing demand for antibodies and assays in pharmaceutical R&D."

• Latin America - US$ 0.25 billion (3% share): Demand is increasing due to "growing adoption of advanced diagnostic assays, strengthening healthcare research ecosystems, and rising prevalence of neurological disorders."

• Middle East & Africa - US$ 0.15 billion (2% share): Growth is supported by "expanding neurological diagnostic capabilities, increased investment in laboratory infrastructure, and rising incidence of CNS-related conditions."

Key Segments

By Product Type
Consumables - Include reagents, assay kits, cartridges, and other recurring supplies; represent the largest share due to frequent usage in diagnostic workflows.

Instruments - Comprise analyzers, detection systems, automation platforms, and laboratory equipment used for performing and interpreting diagnostic tests.

By Technology
Immunoassays / Immunochemistry - Widely adopted for biomarker detection, offering high sensitivity and specificity across various diagnostic applications.

Molecular Diagnostics - Growing rapidly with increasing use of PCR, sequencing, and nucleic acid-based tests for accurate disease detection and research.

Others - Includes chromatography, electrophoresis, mass spectrometry, microfluidics, and emerging hybrid diagnostic platforms.

By End-User
Pharmaceutical & Biotechnology Companies - Major users for drug development, biomarker discovery, quality control, and clinical research applications.

Academic & Research Institutes - Utilize diagnostics technologies for studies in genomics, proteomics, cell biology, and translational research.

Others - Includes contract research organizations (CROs), clinical laboratories, and government or regulatory bodies engaged in diagnostic testing and validation.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/neuroscience-antibodies-and-assays-market?sai-v
Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.